Reciprocal regulation of interleukin‑17A and interleukin‑22 secretion through aryl hydrocarbon receptor activation in CD4<sup>+</sup> T cells of patients with vitiligo

Liu,Baoyi; Xie,Yongyi; Mei,Xingyu; Sun,Yue; Shi,Weimin; Wu,Zhouwei

doi:10.3892/etm.2020.9589

Reciprocal regulation of interleukin‑17A and interleukin‑22 secretion through aryl hydrocarbon receptor activation in CD4⁺ T cells of patients with vitiligo

Authors:
- Baoyi Liu
- Yongyi Xie
- Xingyu Mei
- Yue Sun
- Weimin Shi
- Zhouwei Wu
View Affiliations

Affiliations: Department of Dermatology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, P.R. China
Published online on: December 17, 2020 https://doi.org/10.3892/etm.2020.9589
Article Number: 158
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown the participation of the cytokines interleukin (IL) 17A and IL22 in the development of vitiligo. The aryl hydrocarbon receptor (AhR) functions in the pathogenesis of vitiligo and can modulate cytokine production. The aim of the present study was to determine the relationship between AhR activation and the secretion of IL17A and IL22 in CD4⁺ T cells in vitiligo. A total of 20 newly diagnosed patients with progressive, unstable vitiligo and 20 healthy controls were recruited. CD4⁺ T cells and skin samples were collected. Immunohistochemistry, ELISA, reverse transcription‑quantitative PCR, western blotting and RNA interference experiments were performed. The expression of AhR was significantly lower in the CD4⁺ T cells and skin, both lesional and nonlesional, of patients with vitiligo compared with healthy subjects. AhR expression was markedly lower in nonlesional compared with lesional skin of patients with vitiligo. The expression levels of IL17A and IL22 were significantly higher in patients with vitiligo compared with healthy subjects. Knockdown of AhR significantly increased the production of IL17A and markedly decreased IL22 levels in the CD4⁺ T cells of patients with vitiligo. Ginkgo biloba extract EGb 761 activated AhR, inhibited IL17A secretion and enhanced IL22 release in the CD4⁺ T cells of patients with vitiligo. In conclusion, reduced AhR expression is associated with progressive, unstable vitiligo. Activation of AhR with G. biloba extract EGb 761 may have therapeutic potential for decreasing IL17A levels and increasing IL22 levels in patients with vitiligo.

View Figures

View References

1	Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, et al: Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 25:E1–E13. 2012.PubMed/NCBI View Article : Google Scholar
2	Alikhan A, Felsten LM, Daly M and Petronic-Rosic V: Vitiligo: A comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 65:473–491. 2011.PubMed/NCBI View Article : Google Scholar
3	Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG and Harris JE: Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 77:1–13. 2017.PubMed/NCBI View Article : Google Scholar
4	Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, et al: T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 28:29–39. 2008.PubMed/NCBI View Article : Google Scholar
5	Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, Hu NW, Ma DX, Li ZF, Yang Q, et al: Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 7(e31000)2012.PubMed/NCBI View Article : Google Scholar
6	Behfarjam F, Mansouri P and Jadali Z: Imbalance of Peripheral Blood T Helper Type 17 Responses in Patients with Vitiligo. Iran J Allergy Asthma Immunol. 17:171–178. 2018.PubMed/NCBI
7	Bhardwaj S, Rani S, Srivastava N, Kumar R and Parsad D: Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo. Cytokine. 91:153–161. 2017.PubMed/NCBI View Article : Google Scholar
8	Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB, Li R, Estrada Y, Wen HC, Kimmel GW, et al: Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J Allergy Clin Immunol. 143:2095–2107. 2019.PubMed/NCBI View Article : Google Scholar
9	Sushama S, Dixit N, Gautam RK, Arora P, Khurana A and Anubhuti A: Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-α) in vitiligo-New insight into pathogenesis of disease. J Cosmet Dermatol. 18:337–341. 2019.PubMed/NCBI View Article : Google Scholar
10	Elela MA, Hegazy RA, Fawzy MM, Rashed LA and Rasheed H: Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: A case- controlled study on eighty-four patients. Eur J Dermatol. 23:350–355. 2013.PubMed/NCBI View Article : Google Scholar
11	Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Bhutani T, Wei M, et al: The role of IL-17 in vitiligo: A review. Autoimmun Rev. 15:397–404. 2016.PubMed/NCBI View Article : Google Scholar
12	Mattapallil MJ, Kielczewski JL, Zárate-Bladés CR, St Leger AJ, Raychaudhuri K, Silver PB, Jittayasothorn Y, Chan CC and Caspi RR: Interleukin 22 ameliorates neuropathology and protects from central nervous system autoimmunity. J Autoimmun. 102:65–76. 2019.PubMed/NCBI View Article : Google Scholar
13	Neil JA, Matsuzawa-Ishimoto Y, Kernbauer-Hölzl E, Schuster SL, Sota S, Venzon M, Dallari S, Galvao Neto A, Hine A, Hudesman D, et al: IFN-I and IL-22 mediate protective effects of intestinal viral infection. Nat Microbiol. 4:1737–1749. 2019.PubMed/NCBI View Article : Google Scholar
14	Zenewicz LA: IL-22: There is a gap in our knowledge. Immunohorizons. 2:198–207. 2018.PubMed/NCBI View Article : Google Scholar
15	Hahn ME: Aryl hydrocarbon receptors: Diversity and evolution. Chem Biol Interact. 141:131–160. 2002.PubMed/NCBI View Article : Google Scholar
16	Esser C, Rannug A and Stockinger B: The aryl hydrocarbon receptor in immunity. Trends Immunol. 30:447–454. 2009.PubMed/NCBI View Article : Google Scholar
17	Wu Z, Mei X, Ying Z, Sun Y, Song J and Shi W: Ultraviolet B inhibition of DNMT1 activity via AhR activation dependent SIRT1 suppression in CD4+ T cells from systemic lupus erythematosus patients. J Dermatol Sci. 86:230–237. 2017.PubMed/NCBI View Article : Google Scholar
18	Wu Z, Uchi H, Morino-Koga S, Nakamura-Satomura A, Kita K, Shi W and Furue M: Z-Ligustilide inhibits benzo(a)pyrene-induced CYP1A1 upregulation in cultured human keratinocytes via ROS-dependent Nrf2 activation. Exp Dermatol. 23:260–265. 2014.PubMed/NCBI View Article : Google Scholar
19	Rekik R, Ben Hmid A, Lajnef C, Zamali I, Zaraa I and Ben Ahmed M: Aryl hydrocarbon receptor (AhR) transcription is decreased in skin of vitiligo patients. Int J Dermatol. 56:1509–1512. 2017.PubMed/NCBI View Article : Google Scholar
20	Schallreuter KU, Salem MA, Gibbons NC, Maitland DJ, Marsch E, Elwary SM and Healey AR: Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: Epidermal H2O2/ONOO(-)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling. FASEB J. 26:2471–2485. 2012.PubMed/NCBI View Article : Google Scholar
21	Tsuji G, Hashimoto-Hachiya A, Takemura M, Kanemaru T, Ichihashi M and Furue M: Palladium and platinum nanoparticles activate AHR and NRF2 in human keratinocytes-implications in vitiligo therapy. J Invest Dermatol. 137:1582–1586. 2017.PubMed/NCBI View Article : Google Scholar
22	DeFeudis FV: A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry. 36 (Suppl 1):S2–S7. 2003.PubMed/NCBI View Article : Google Scholar
23	Parsad D, Pandhi R and Juneja A: Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 28:285–287. 2003.PubMed/NCBI View Article : Google Scholar
24	Szczurko O and Boon HS: A systematic review of natural health product treatment for vitiligo. BMC Dermatol. 8(2)2008.PubMed/NCBI View Article : Google Scholar
25	Szczurko O, Shear N, Taddio A and Boon H: Ginkgo biloba for the treatment of vitilgo vulgaris: An open label pilot clinical trial. BMC Complement Altern Med. 11(21)2011.PubMed/NCBI View Article : Google Scholar
26	Whitton ME, Ashcroft DM and González U: Therapeutic interventions for vitiligo. J Am Acad Dermatol. 59:713–717. 2008.PubMed/NCBI View Article : Google Scholar
27	Koltermann A, Hartkorn A, Koch E, Fürst R, Vollmar AM and Zahler S: Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. 64:1715–1722. 2007.PubMed/NCBI View Article : Google Scholar
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
29	Wu Z, Uchi H, Morino-Koga S, Shi W and Furue M: Z-ligustilide ameliorated ultraviolet B-induced oxidative stress and inflammatory cytokine production in human keratinocytes through upregulation of Nrf2/HO-1 and suppression of NF-κB pathway. Exp Dermatol. 24:703–708. 2015.PubMed/NCBI View Article : Google Scholar
30	Behfarjam F and Jadali Z: Vitiligo patients show significant up-regulation of aryl hydrocarbon receptor transcription factor. An Bras Dermatol. 93:302–303. 2018.PubMed/NCBI View Article : Google Scholar
31	Wang X, Li K, Liu L, Shi Q, Song P, Jian Z, Guo S, Wang G, Li C and Gao T: AHR promoter variant modulates its transcription and downstream effectors by allele-specific AHR-SP1 interaction functioning as a genetic marker for vitiligo. Sci Rep. 5(13542)2015.PubMed/NCBI View Article : Google Scholar
32	Rohlman D, Pham D, Yu Z, Steppan LB and Kerkvliet NI: Aryl Hydrocarbon Receptor-Mediated Perturbations in Gene Expression during Early Stages of CD4(+) T-cell Differentiation. Front Immunol. 3(223)2012.PubMed/NCBI View Article : Google Scholar
33	Alam MS, Maekawa Y, Kitamura A, Tanigaki K, Yoshimoto T, Kishihara K and Yasutomo K: Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci USA. 107:5943–5948. 2010.PubMed/NCBI View Article : Google Scholar
34	Azizi G, Yazdani R and Mirshafiey A: Th22 cells in autoimmunity: A review of current knowledge. Eur Ann Allergy Clin Immunol. 47:108–117. 2015.PubMed/NCBI
35	Benghiat FS, Charbonnier LM, Vokaer B, De Wilde V and Le Moine A: Interleukin 17-producing T helper cells in alloimmunity. Transplant Rev (Orlando). 23:11–18. 2009.PubMed/NCBI View Article : Google Scholar
36	Basak PY, Adiloglu AK, Ceyhan AM, Tas T and Akkaya VB: The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 60:256–260. 2009.PubMed/NCBI View Article : Google Scholar
37	Bassiouny DA and Shaker O: Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 36:292–297. 2011.PubMed/NCBI View Article : Google Scholar
38	Tembhre MK, Sharma VK, Sharma A, Chattopadhyay P and Gupta S: T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta. 424:27–32. 2013.PubMed/NCBI View Article : Google Scholar
39	Plé C, Fan Y, Ait Yahia S, Vorng H, Everaere L, Chenivesse C, Balsamelli J, Azzaoui I, de Nadai P, Wallaert B, et al: Polycyclic aromatic hydrocarbons reciprocally regulate IL-22 and IL-17 cytokines in peripheral blood mononuclear cells from both healthy and asthmatic subjects. PLoS One. 10(e0122372)2015.PubMed/NCBI View Article : Google Scholar
40	Rajaraman G, Yang G, Chen J and Chang TK: Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can J Physiol Pharmacol. 87:674–683. 2009.PubMed/NCBI View Article : Google Scholar
41	Jin UH, Park H, Li X, Davidson LA, Allred C, Patil B, Jayaprakasha G, Orr AA, Mao L, Chapkin RS, et al: Structure-dependent modulation of aryl hydrocarbon receptor-mediated activities by flavonoids. Toxicol Sci. 164:205–17. 2018.PubMed/NCBI View Article : Google Scholar
42	Pang C, Zhu C, Zhang Y, Ge Y, Li S, Huo S, Xu T, Stauber RH and Zhao B: 2,3,7,8-Tetrachloodibenzo-p-dioxin affects the differentiation of CD4 helper T cell. Toxicol Lett. 311:49–57. 2019.PubMed/NCBI View Article : Google Scholar